Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Go back to Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 59.35 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.35 | 52 Week High | $0.52 | |||
| Open | $59.35 | 52 Week Low | $0.08 | |||
| Day High | $59.35 | P/E | N/A | |||
| Day Low | $59.35 | EPS | $-3.80 | |||
| Volume | 90,052 | |||||
